Medicamen Biotech Ltd

Medicamen Biotech Ltd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.15, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.89, suggesting it can cover its short-term obligations but with limited excess capacity. However, the operating cash flow is negative at -67.4 million INR, and capital expenditures are also negative at -62.9 million INR, indicating ongoing investment in long-term assets or operational expansion.

Profitability metrics show a return on equity (ROE) of 1.03% and a return on assets (ROA) of 0.72%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The company's net income of 21.3 million INR is modest relative to its total assets of 2.95 billion INR, suggesting limited efficiency in converting assets into profit. Gross profit of 237.2 million INR represents 50.1% of total revenue, which is in line with industry norms but does not indicate a strong margin advantage.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segmental or geographic breakdown limits the ability to assess exposure to regional or product-specific risks. The absence of detailed segment reporting also makes it difficult to evaluate the performance of individual product lines or therapeutic areas.

Looking ahead, the company's growth trajectory is uncertain. No specific revenue growth rates or outlooks are provided in the available data, and the absence of forward-looking guidance from the company or industry benchmarks makes it difficult to assess future performance. The capital expenditures suggest ongoing investment, but the negative operating cash flow indicates that these investments are not yet generating positive cash returns.

Risk factors include a medium liquidity risk, as the company's operating cash flow is negative and its net cash position is negative after subtracting total debt. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. However, the company's reliance on operating cash flow to fund its operations and capital expenditures could increase financial risk if revenue growth does not accelerate.

Recent events and disclosures are limited in the available data. No specific filings, earnings calls, or regulatory updates are cited in the provided information. The company's financial statements do not include detailed explanations of recent strategic moves or operational changes, which limits the ability to assess the impact of external factors on its performance.

Medicamen Biotech generated INR 1.63 billion in revenue for the latest fiscal year, demonstrating significant top-line scale.

Net margin of 4.5% exceeds the pharmaceutical cohort median of 3.86%, indicating relatively strong profitability efficiency.

Free cash flow improved by 12.5% year-over-year to INR 101.6 million, showing enhanced cash generation capability.

The debt-to-equity ratio of 0.15 is lower than the cohort median of 0.18, suggesting a conservative leverage profile.

The company faces high credit risk and medium liquidity risk, posing potential financial stability challenges for investors.

Revenue INR 1.79B, +27,3% YoY; Operating income −13,1% YoY.

• ▍Revenue INR 1.79B, +27,3% YoY
• ▍Operating income −13,1% YoY
• ▍Net income −26,4% YoY
• ▍Free cash flow −31,7% YoY
• ▍Net margin 6.1%

Revenue INR 1.41B, +22,0% YoY; Operating income −1,5% YoY.

• ▍Revenue INR 1.41B, +22,0% YoY
• ▍Operating income −1,5% YoY
• ▍Net income −0,4% YoY
• ▍Free cash flow +22,1% YoY
• ▍Net margin 10.5%

Revenue INR 1.15B, +2,4% YoY; Operating income +6,4% YoY.

• ▍Revenue INR 1.15B, +2,4% YoY
• ▍Operating income +6,4% YoY
• ▍Net income +22,8% YoY
• ▍Free cash flow +376,0% YoY
• ▍Net margin 12.9%

Revenue INR 1.13B; Operating income INR 168.3M.

• ▍Revenue INR 1.13B
• ▍Operating income INR 168.3M
• ▍Net margin 10.8%